The Reagan-Udall Foundation Bylaws, 68028-68034 [E9-30409]
Download as PDF
68028
Notices
Federal Register
Vol. 74, No. 244
Tuesday, December 22, 2009
This section of the FEDERAL REGISTER
contains documents other than rules or
proposed rules that are applicable to the
public. Notices of hearings and investigations,
committee meetings, agency decisions and
rulings, delegations of authority, filing of
petitions and applications and agency
statements of organization and functions are
examples of documents appearing in this
section.
REAGAN–UDALL FOUNDATION
The Reagan-Udall Foundation Bylaws
ACTION:
Notice; request for comments.
SUMMARY: The Reagan-Udall
Foundation, which was created by Title
VI of the Food and Drug Administration
Amendments of 2007, is publishing the
bylaws that were adopted by its Board
of Directors, for public comment.
DATES: Submit e-mail comments to:
Comments@ReaganUdall.org on or
before January 21, 2010.
FOR FURTHER INFORMATION CONTACT: Jane
Reese-Coulbourne, The Reagan-Udall
Foundation, (202) 783–7877,
JRCoulbourne@ReaganUdall.org.
SUPPLEMENTARY INFORMATION:
srobinson on DSKHWCL6B1PROD with NOTICES
I. Background
On September 27, 2007, the President
signed into law the Food and Drug
Administration Amendments Act of
2007 (FDAAA). Title VI of the law
creates the Reagan-Udall Foundation,
the purpose of which is to ‘‘advance the
mission of the Food and Drug
Administration to modernize medical,
veterinary, food, food ingredient and
cosmetic products development,
accelerate innovation, and enhance
product safety.’’ See section 770(b) of
the act (21 U.S.C. 379dd (b)). The duties
of the Foundation include the
identification of unmet needs in the
development, manufacture, and
evaluation (including postmarket
evaluation) of the safety and
effectiveness of Food and Drug
Administration (FDA)-regulated
products, and the establishment of
scientific and other projects and
programs to meet those needs. See
section 770(c) (21 U.S.C. 379dd(c)).
Among the areas where experts inside
and outside the FDA believe the
Foundation can support better science
are:
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
• Scientific fellowships and programs
to improve the scientific capacity of the
FDA;
• Public-private collaboration to
enhance the capacity and techniques for
monitoring the safety of medical
products on the market;
• Development of methods and
analyses to promote the safety and
effectiveness of medical products and
foods; and
• Improvements in the science and
technical capabilities of food safety.
The Foundation’s Board of Directors
has adopted an initial set of bylaws, an
important step toward its initiation of
activity as a nonprofit organization.
Pursuant to section 770(d)(2) of the act
(21 U.S.C. 379dd(d)(2)), these bylaws
are being published in the Federal
Register for public comment. The
bylaws include provisions on conflicts
of interest and the acceptance of
donations and grants. The Foundation is
committed to the highest standards of
science in support of FDA’s mission. As
the Foundation develops additional
information regarding the types of
donations and grants (referred to in the
bylaws as ‘‘gifts’’) it may receive and the
types of projects it will undertake and
fund, it will adopt additional policies
regarding conflicts of interest and other
issues. In addition, as the Foundation
gains more experience, it will develop
detailed policies and procedures
regarding gift review and acceptance
policies. The Foundation will make
these policies and procedures available
to the public. Until that time, the
Foundation will not accept donations or
grants from entities subject to FDA
regulation or trade associations of
industries subject to FDA regulation.
The Board will also monitor the terms
of any individual donation or grant.
II. Bylaws of Reagan-Udall Foundation,
Inc., for the Food and Drug
Administration (Adopted by the
Board of Directors on October 3,
2009)
Article I
Offices
Section 1. Principal Office. The
principal office of the Foundation shall
be at such location as the Board of
Directors designates, however, such
location shall, if practicable be located
not more than 20 miles from the District
of Columbia.
PO 00000
Frm 00001
Fmt 4703
Sfmt 4703
Section 2. Other Offices. The
Foundation may also have an office or
offices other than said principal office at
such place or places as the Board of
Directors shall from time to time
determine or the business of the
Foundation may require. Such other
offices shall also, if practicable, be
located not more than 20 miles from the
District of Columbia.
Article II
Mission
Section 1. Mission. The Foundation is
organized as a non-profit organization
exclusively for charitable, scientific and
educational purpose as specified in
section 501(c)(3) of the Internal Revenue
Code of 1986 and Section 770 of the
Federal Food Drug and Cosmetic Act (21
U.S.C. 379dd). The purpose of the
Foundation shall be to advance the
mission of the Food and Drug
Administration to modernize medical,
veterinary, food, food ingredient, and
cosmetic product development,
accelerate innovation, and enhance
product safety.
Article III
Members
The Foundation shall have no
members. All authority that would
otherwise be vested in or exercised by
members shall be vested in the Board of
Directors of the Foundation. Nothing in
these bylaws shall be interpreted as
requiring the Board of Directors to meet,
vote, or otherwise act separately as
members of the Foundation in order to
exercise powers that would, if there
were members of the Foundation, be
vested in the members.
Article IV
Board of Directors
Section 1. General Powers. The
business and affairs of the Foundation
shall be managed under the direction of
the Board of Directors. The Board of
Directors may exercise all such
authority and powers of the Foundation
and do all such lawful acts and things
as provided by statute or the Articles of
Incorporation.
Section 2. Composition, Number and
Appointment. The Board of Directors of
the Foundation shall be composed of 16
members, two ex officio members (nonvoting) and 14 appointed (voting)
members. The ex officio members shall
E:\FR\FM\22DEN1.SGM
22DEN1
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
be the following individuals or their
designees: The Commissioner of Food
and Drugs and the Director of the
National Institutes of Health. Of the
fourteen appointed (voting) members,
no more than four members shall be
representatives of the general
pharmaceutical, device, food, cosmetic
and biotechnology industries; three
shall be representatives of academic
research organizations; two shall be
representatives of patient or consumer
advocacy organizations, one shall be a
representative of health care providers;
and four or more shall be at large
members with expertise or experience
relevant to the purpose of the
Foundation. No employee of the Federal
Government shall be appointed as a
member of the Board.
Section 3. Terms of Office. The term
of office of each appointed member of
the Board shall be four years except that
the terms of offices for the initial
appointed members of the Board shall
expire on a staggered basis as follows:
one industry representative, one
academic research representative, and
one at-large representative each shall
have an initial appointment of two
years; two industry representatives, one
at-large representative, one academic
research representative, and one
patient/consumer representative each
shall have an initial term of three years;
and one industry representative, two atlarge representatives, one academic
research representative, one patient/
consumer representative, and the one
health care provider representative each
shall have an initial term of four years.
A member of the Board of Directors may
continue to serve after the expiration of
his or her term until a successor is
appointed. A member of the Board of
Directors may be reappointed for a
subsequent term or terms. If a member
of the Board does not serve the full
term, described herein, the individual
appointed, pursuant to section 10, to fill
the resulting vacancy shall be appointed
for the remainder of the term of the
predecessor of the individual.
Section 4. Annual Meeting and
Annual Reporting. (a) The annual
meeting of the Board of Directors shall
be held at such time, but in no event
later than the end of the fifth month
following the end of the fiscal year of
the Foundation, and at such place as
shall be specified in a notice thereof
given as hereinafter provided in section
7 of this Article IV or waiver of notice.
(b) The annual meeting shall be open to
the public. (c) At the annual meeting the
Foundation shall publish a report for
the preceding fiscal year, which shall
include a comprehensive statement of
the operations, activities, financial
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
condition and accomplishments of the
Foundation. (d) The Foundation shall
make copies of each report submitted
under this section 4 of Article IV
available to any person for a charge not
exceeding the cost of providing such
copy.
Section 5. Regular Meeting. Regular
meetings of the Board of Directors shall
be held at such time and place as the
Board of Directors may fix.
Section 6. Special Meetings. Special
meetings of the Board of Directors may
be called at any time or at the request
of the Chair of the Board or the
Executive Director. The person or
persons authorized to call special
meetings of the Board may fix the time
and place for holding such special
meeting.
Section 7. Notice. Annual and special
meetings of the Board of Directors shall
be held on notice to the directors.
Notice shall state the time and place of
the meeting and, in the case of a special
meeting, the purpose or purposes for
holding such meeting. Notice of each
such meeting shall be sent by electronic
mail or mailed, postage prepaid, to each
director, addressed to him or her at his
or her address as shown by the records
of the Foundation, at least ten days
before the day on which such meeting
is to be held, or under extraordinary
circumstances be delivered to him or
her personally or be given to him or her
by telephone, or other similar means, at
least twenty-four hours before the time
at which such meeting is to be held.
Notice of any such meeting need not be
given to any director who submits a
signed waiver of notice before the
meeting or who attends such meeting
without protesting, prior to or at its
commencement, the lack of notice to
him or her.
Section 8. Quorum. A majority of the
voting members of the entire Board of
Directors shall constitute a quorum for
purposes of conducting the business at
any meeting of the Board of Directors;
but if less than a majority of the voting
directors are present at said meeting, a
majority of the voting directors present
may adjourn the meeting from time to
time without further notice. The Chair
may, under extraordinary
circumstances, in his of her discretion,
require the vote of the full Board (all
voting members) on a particular matter,
provided the Chair discloses to the
Board the basis for requiring such a
vote. When the vote of the full Board is
required, voting members will be
permitted to vote at a meeting of the
Board or by submitting his or her vote
to the Chair in writing.
Section 9. Manner of Acting. The act
of a majority of the voting directors
PO 00000
Frm 00002
Fmt 4703
Sfmt 4703
68029
present at a meeting at which a quorum
is present shall be the act of the Board
of Directors, unless the act of a greater
number is required by law or these
Bylaws.
Section 10. Vacancies. Any vacancy
in the membership of the Board shall
not affect the power of the remaining
directors to execute the duties of the
Board and any such vacancy shall be
filled promptly by appointment by the
appointed directors by majority vote.
Section 11. Resignations. Any
appointed member of the Board of
Directors may resign at any time by
giving written notice of his or her
resignation to the Board of Directors, the
Chair of the Board, the Executive
Director or the Secretary. Any such
resignation shall take effect at the time
specified therein if later than the date of
its receipt, or if the time when it shall
become effective is not specified
therein, immediately upon its receipt.
Unless otherwise specified therein, the
acceptance of such resignation shall not
be necessary to make it effective.
Section 12. Removal of Directors.
Except as otherwise provided by statute,
any director may be removed for cause
by the vote of a majority of the voting
members of the Board of Directors then
in office. The failure to participate in at
least half of the meetings and calls
scheduled over a one year period shall
be a basis for such removal.
Section 13. Compensation. Members
of the Board may not receive
compensation for service on the Board.
Directors may be reimbursed for travel,
the reasonable cost of meals and
lodging, and other necessary expenses
incurred in carrying out the duties of
the Board, as set forth in these Bylaws.
Section 14. Informal Action by Board
of Directors. Any action required or
permitted by law to be taken at a
meeting of the Board of Directors may
be taken without a meeting if a
unanimous written consent, which sets
forth the action to be taken, shall be
signed by each voting member of the
Board and filed with the minutes of
proceedings of the Board.
Section 15. Telephonic Meeting.
Members of the Board may participate
in a meeting by means of a telephone
conference or similar communications
equipment if all persons participating in
the meeting can hear each other at the
same time.
Section 16. Emeritus Directors. The
Board of Directors may from time to
time appoint a former director to the
honorary position of ‘‘Director
Emeritus.’’ Unless otherwise determined
by the Board of Directors, the
appointment of a Director Emeritus
shall continue in effect for the
E:\FR\FM\22DEN1.SGM
22DEN1
68030
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
remainder of the person’s life. A former
director holding such honorary position
shall be entitled to receive notice of, and
to attend meetings or portions of
meetings of the Board of Directors, but
shall have no voting or other rights of
a director.
Article V
srobinson on DSKHWCL6B1PROD with NOTICES
Committees
Section 1. Committees. The Board of
Directors, by resolution adopted by a
majority of the voting directors in office,
shall designate and appoint an
Executive Committee, a Governance
Committee and a Finance Committee,
and may designate and appoint one or
more other committees each of which
shall consist of two or more directors,
and delegate to such committees any of
the powers of the Board of Directors,
except the power to amend, alter, and
repeal the Bylaws; to elect, appoint or
remove any member of such committee
or any member of the Board or any
officer of the Foundation; to amend or
restate the Articles of Incorporation; or
to adopt a plan of merger or
consolidation with another corporation.
The appointment of any committee, the
delegation of authority to it, or action by
it under that authority shall not operate
to relieve the Board of Directors, or any
individual member of the Board, of any
responsibility imposed upon it or upon
him or her by law.
Section 2. Executive Committee. The
Executive Committee shall carry out the
responsibilities of the Board of Directors
between meetings of the Board of
Directors.
The Chair of the Board shall be chair
of the Executive Committee and the
Secretary of the Foundation shall act as
secretary thereof. The Chairs of the
Governance and Finance Committees
shall be members of the Executive
Committee. The Executive Director shall
be an ex officio, non-voting member of
the Executive Committee. In the absence
of the Chair, Executive Director or
Secretary at any meeting of the
Executive Committee, the committee
shall appoint a chair or secretary of the
meeting as the case may be.
Section 3. Governance Committee.
The Governance Committee shall be
responsible for making
recommendations to the Board on all
matters affecting governance, reviewing
the Board’s performance policies and
these Bylaws, and making
recommendations to the Board for
director nominees and Officer
appointments. The Vice Chair of the
Board shall chair the Governance
Committee.
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
Section 4. Finance Committee. The
Finance Committee shall be responsible
for developing and reviewing fiscal
procedures and shall make
recommendations to the Board
regarding the budget and other financial
matters. The Treasurer of the
Foundation shall chair the Finance
Committee.
Section 5. Term of Office. All
committees of the Board of Directors
shall serve at the pleasure of the Board
of Directors. Members of committees
who are designated by the Board of
Directors shall serve at the pleasure of
the Board of Directors. Each chair of a
committee shall hold such office for one
year and until his or her death,
resignation or removal, whichever
occurs first. A chair of a committee may
continue to serve as chair after the
expiration of his or her term until a
successor is appointed.
Section 6. Organization, Meetings of
Committees. The Board of Directors
shall appoint one member of each of the
other committees that may be created to
be the chair of such committee. All
committees may adopt rules governing
the time, or the method of call or
holding their meetings, and the conduct
of their affairs. All committees shall
keep a record of their acts and
proceedings and shall report thereon to
the Board of Directors.
Section 7. Vacancies. A vacancy in
the membership of any committee may
be filled by appointments made in the
same manner as provided in the case of
the original appointments.
Section 8. Quorum. Unless otherwise
provided in the resolution of the Board
of Directors designating a committee, a
majority of the whole committee shall
constitute a quorum and the act of a
majority of the members present at a
meeting at which a quorum is present
shall be the act of the committee.
Article VI
Officers, Employees, Agents and
Contractors
Section 1. Number and Qualifications
of Officers. The Officers of the
Foundation (except for the initial Chair,
which shall be appointed by the exofficio directors) shall be elected by the
Board of Directors and shall include the
Chair and Vice Chair of the Board, the
Secretary, the Treasurer, and any other
officers as may be necessary or desirable
for the business of the Foundation.
Section 2. Election and Term of
Office. The officers of the Foundation,
except the Chair of the Board, shall be
elected annually by the members of the
Board of Directors at its annual meeting.
Each such officer shall hold office until
PO 00000
Frm 00003
Fmt 4703
Sfmt 4703
death, resignation, removal or until the
next annual meeting of the Board of
Directors and until his or her successor
shall be duly elected. The members of
the Board of Directors shall elect a
member of the Board to serve as the
Chair of the Board, who shall serve
through the end of his or her term. An
officer may be re-elected for subsequent
terms.
Section 3. Resignations. Any officer of
the Foundation may resign at any time
by giving written notice of his or her
resignation to the Board of Directors, the
Chair of the Board, the Executive
Director or the Secretary. Any such
resignation shall take effect at the time
specified therein or, if the time when it
shall become effective is not specified
therein, immediately upon its receipt.
Unless otherwise specified therein, the
acceptance of any such resignation shall
not be necessary to make it effective.
Section 4. Removal. Any officer of the
Foundation elected or appointed by the
Board of Directors may be removed by
an affirmative vote of a majority of the
then incumbent voting members of the
Board of Directors whenever in its
judgment the best interests of the
Foundation would be served thereby,
but such removal shall be without
prejudice to the contract rights, if any,
of the officer so removed.
Section 5. Vacancies. A vacancy in
any office because of death, resignation,
removal, disqualification or otherwise
shall be filled by the vote of a majority
of the voting members of the Board of
Directors for the unexpired portion of
the term.
Section 6. Chair of the Board. The
Chair of the Board shall be a member of
the Board, an officer of the Foundation
and, if present, shall preside at each
meeting of the Board of Directors. He or
she shall advise and counsel with the
Executive Director and in his or her
absence with the other officers of the
Foundation, and shall perform such
other duties as may from time to time
be assigned to him or her by the Board
of Directors.
Section 7. Vice-Chair of the Board.
The Vice-Chair of the Board shall be a
member of the Board, an officer of the
Foundation and, if present, shall preside
at each meeting of the Board of Directors
at which the Chair of the Board is not
present, and shall perform the other
duties of the Chair of the Board during
such times as the Chair of the Board is
unavailable to perform such duties.
Section 8. Treasurer. The Treasurer
shall be a member of the Board and
shall (a) Have charge and custody of,
and be responsible for, all the funds and
securities of the Foundation; (b) keep or
cause to be kept full and accurate
E:\FR\FM\22DEN1.SGM
22DEN1
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
accounts of receipts and disbursements
in books belonging to the Foundation;
(c) deposit or cause to be deposited all
moneys and other valuables to the credit
of the Foundation in such depositories
as may be designated by the Board of
Directors or pursuant to its direction; (d)
receive, and give receipts for, moneys
due and payable to the Foundation from
any source whatsoever; (e) disburse the
funds of the Foundation; (f) render to
the Board of Directors, whenever the
Board of Directors may require, an
account of the financial condition of the
Foundation; and (g) in general, perform
all duties incident to the office of
Treasurer and such other duties as from
time to time may be assigned to him or
her by the Board of Directors.
Section 9. Secretary. The Secretary
shall be a member of the Board and
shall (a) Keep or cause to be kept the
minutes of all meetings of the Board of
Directors; (b) see that all notices are
duly given in accordance with the
provisions of these Bylaws and as
required by law; (c) be custodian of the
records and the seal of the Foundation
and affix and attest the seal to all other
documents to be executed on behalf of
the Foundation under its seal; (d) see
that the books, reports, statements,
certificates, and other documents and
records required by law to be kept and
filed are properly kept and filed; (e) in
general, perform all duties incident to
the office of Secretary and such other
duties as from time to time may be
assigned to him or her by the Board of
Directors.
Section 10. Executive Director. The
Board of Directors shall appoint an
Executive Director who shall serve at
the pleasure of the Board of Directors.
The Executive Director shall be the chief
executive officer of the Foundation who
shall be responsible for the day-to-day
operations of the Foundation. If the
Board of Directors has not elected a
Chair or Vice Chair of the Board or if the
Chair and Vice Chair of the Board are
absent, the Executive Director shall
preside at such meeting of the Board of
Directors. He or she shall perform all
duties incident to the office of the
Executive Director and such other
duties as may from time to time be
assigned to him or her by the Board of
Directors.
Section 11. Compensation. The
Foundation may pay reasonable
compensation for services rendered by
employees of the Foundation. All
amounts paid as compensation by the
Foundation to any employee shall be
approved by the Board of Directors. The
compensation of the Executive Officer
shall not be greater than the
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
compensation of the Commissioner of
the Food and Drug Administration.
Section 12. Agents and Contractors.
The Executive Director shall be
responsible for hiring, promoting, and
discharging all other employees and
agents of the Foundation. The Executive
Director shall also be responsible for
defining the duties of such employees
and agents and determining the
compensation to be paid to such
employees.
Article VII
Conflicts of Interest
Section 1. General Policy. No director,
officer, employee, fellow or trainee of
the Foundation (hereinafter ‘‘Interested
Persons’’) shall take any action on or
participate in the consideration or
determination of any Foundation matter
in which he or she, his or her spouse,
minor child, general partner, nonfederal organization in which he or she
is serving as an officer, director, trustee,
general partner or employee, or any
person or nonfederal organization with
whom he or she is negotiating or has
any arrangement concerning potential
employment, has a financial interest.
Section 2. Responsibilities of
Interested Persons. In addition to actual
conflicts of interest, Interested Persons
are also obliged to avoid actions that
could be perceived or interpreted to be
in conflict with the Foundation’s best
interests. Interested Persons shall
disclose their financial interest in
entities doing business with the
Foundation and refrain from
participating in decisions affecting
transactions between the Foundation
and those other entities without
approval by the Board of Directors.
Section 3. Additional Conflict of
Interest Policies and Procedures.
Appendix A to these Bylaws includes
more detailed policies and procedures
for identifying and managing conflicts
of interest.
Section 4. Oversight Responsibilities.
The Chair of the Board shall be
responsible for the application of the
Foundation’s conflicts of interest
policies and procedures to Board
Members, committee members, and the
Executive Director. The Executive
Director shall be responsible for the
application and interpretation of this
policy as it relates to all other
employees, fellows, and trainees.
Section 5. Project Specific Conflicts
Policies. The Foundation shall, as
appropriate, develop conflicts of interest
policies and procedures specific to an
individual project and/or consortium
developed to carry out the goals of the
Foundation. Such policies and
PO 00000
Frm 00004
Fmt 4703
Sfmt 4703
68031
procedures shall be made available to
the public.
Article VIII
Acceptance of Donations and Grants
Section 1. General Policy. It shall be
the policy of the Foundation to accept
donations and grants (hereinafter
‘‘Gifts’’) that further its missions,
supporting the Food and Drug
Administration. This mission is realized
through Gifts that support the programs
and projects of the Foundation, Gifts
that secure the operation and future
growth of the Foundation, or Gifts that
otherwise facilitate the Foundation in
providing services to the Food and Drug
Administration. The Board of Directors
shall develop and adopt detailed Gift
review and acceptance policies and
procedures that define what constitutes
acceptable Gifts. Such policies and
procedures shall be made available to
the public. The Board of Directors shall
be responsible for ensuring that the
requirements of this Article VIII and the
Foundation’s Gift policies and
procedures are met.
Section 2. Review of Gifts. The Board
of Directors has the discretion to accept
or refuse all Gifts and is charged with
the responsibility of reviewing and
properly screening all Gifts made to the
Foundation. The Board of Directors
shall determine whether acceptance of a
gift will reflect unfavorably on, or
compromise the integrity of the
Foundation. The Board of Directors
shall have the discretion to refuse any
Gift that is deemed inappropriate for
any reason, such as the appearance of,
or an actual conflict of interest,
unreasonable or burdensome
restrictions, costs to the Foundation in
fulfilling the terms of, or administering
the Gift, or any other reason. The Board
of Directors shall make decisions
regarding acceptance or refusal of gifts
by a majority of voting members present
at a regularly scheduled meeting of the
Board or by a majority of all voting
members if the decision is made
between regularly scheduled meetings.
If a vote is taken between regularly
scheduled meetings, members may vote
in writing by regular mail or e-mail.
Section 3. Restrictions on Gifts. The
Foundation will accept unrestricted
Gifts. The Foundation may also accept
Gifts for specific programs and
purposes, provided such Gifts are not
inconsistent with its mission, purposes,
and priorities. The Foundation will not
accept Gifts that are too restrictive in
purpose or otherwise inappropriate.
Section 4. Availability of Information
on Gift Acceptance. Information about
E:\FR\FM\22DEN1.SGM
22DEN1
68032
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
the Foundation’s acceptance of Gifts
shall be made available to the public.
Article IX
Grants and Contracts
Section 1. Grantee/Contractor
Selection and Award Principles. The
selection and award of grants and/or
contracts by the Foundation will be
conducted to ensure fairness,
impartiality, and inclusiveness. All
grant and contract awards shall be
approved by the Board of Directors.
Section 2. Solicitation. The
Foundation will take reasonable steps to
make each solicitation widely known to
the public.
Section 3. Peer Review. An objective
peer-review process will be used to
assess responses to solicitations and
provide recommendations to the Board
of Directors.
Section 4. Objectivity. All reviews and
assessments shall be made objectively
and shall not be based on commercial or
proprietary interests.
Section 5. Conflicts of Interest. All
participants involved in the
development, review, and selection
process shall abide by the Foundation’s
Conflict of Interest policies.
Section 6. Administrative Expenses
Cap. Grants, contracts and cooperative
agreements shall provide that the
administrative expenses allocable to
funds provided by the Foundation not
exceed 25%.
Section 7. Exclusions. This Article
shall not apply to the selection and
award of grants and contracts related to
running the day-to-day operations of the
Foundation.
srobinson on DSKHWCL6B1PROD with NOTICES
Article X
Information and Inventions
Section 1. Information and Data. All
information and data developed by the
Foundation or with Foundation funds
shall be released and published, to the
extent practicable, to maximize their use
by the Food and Drug Administration,
nonprofit organizations and academic
and industrial researchers to further the
goals and priorities of the Foundation.
The Foundation may charge cost-based
fees for published materials produced
by the Foundation.
Section 2. Inventions. The Foundation
shall ensure that (a) Action is taken to
obtain patents for inventions developed
by the Foundation or with funds from
the Foundation; (b) action is taken to
enable the licensing of such inventions;
and (c) executed licenses, memoranda of
understanding, material transfer
agreements, contracts and other such
instruments promote, to the maximum
extent practicable, the broadest
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
Article XIII
Board of Directors may in its discretion
impose in general or particular cases or
classes of cases, any person who is
threatened to be made a party to any
threatened, pending or completed
action, suit, or proceeding, whether
civil, criminal, administrative or
investigative, by reason of the fact that
he or she is or was a Director or officer
of the Foundation shall be indemnified
by the Foundation against judgments,
penalties, fines, settlements, and
reasonable expenses, including
attorney’s fees, actually and necessarily
incurred by him or her in connection
with such action, suit or proceeding, or
in connection with any appeal therein
(which reasonable expenses may be
paid or reimbursed in advance of final
disposition of any such suit, action, or
proceeding subject to the receipt of a
written undertaking to repay such
expenses in the event that such person
is determined not to be entitled to be
indemnified).
Section 2. Employees and Agents. To
the maximum extent permitted by the
laws of the State of Maryland in effect
from time to time, and subject to
compliance with any procedures and
other requirements prescribed by said
laws and by such rules and regulations,
not inconsistent with said laws, as the
Board of Directors may in its discretion
impose in general or particular cases or
classes of cases, any person who is
threatened to be made a party to any
threatened, pending or completed
action, suit, or proceeding, whether
civil, criminal, administrative or
investigative, by reason of the fact that
he or she is or was an employee or agent
of the Foundation may (but need not) be
indemnified by the Foundation against
judgments, penalties, fines, settlements,
and reasonable expenses, including
attorney’s fees, actually and necessarily
incurred by him or her in connection
with such action, suit or proceeding, or
in connection with any appeal therein
(which reasonable expenses may be
paid or reimbursed in advance of final
disposition of any such suit, action, or
proceeding subject to the receipt of a
written undertaking to repay such
expenses in the event that such person
is determined not to be entitled to be
indemnified).
Indemnification
Article XIV
Section 1. Officers and Directors. To
the maximum extent permitted by the
laws of the State of Maryland in effect
from time to time, and subject to
compliance with any procedures and
other requirements prescribed by said
laws and by such rules and regulations,
non inconsistent with said laws, as the
General Provisions
Section 1. Seal. The seal of the
Foundation shall be in such form as
shall be approved by the Board of
Directors.
Section 2. Fiscal Year. The fiscal year
of the Foundation shall end on
December 31 of each year or on such
conversion to commercial and
noncommercial applications of licensed
and patented inventions of the
Foundation to further the goals and
priorities of the Foundation. The
Foundation may, consistent with the
policy to support the widest and least
restrictive use of inventions, charge a
reasonable royalty for the use of such
inventions.
Article XI
Training Fellowships
The Foundation will establish
fellowships for: Scientists, doctors and
other professionals, who are not
employees of any FDA-regulated
industry; FDA professionals to obtain
training outside the agency; and nonFDA professionals to obtain training at
the Foundation, academic or scientific
institutions or the FDA. The purpose of
such fellowships shall be to foster
greater understanding of and expertise
in new scientific tools, diagnostics,
manufacturing techniques, and potential
barriers to translating basic research into
clinical and regulatory practice, train
scientific or regulatory professionals in
regulatory science and policy, and
increase the exchange of scientific
information between FDA and external
entities.
Article XII
Memoranda of Understanding and
Cooperative Agreements
Section 1. Review. All memoranda of
understanding and cooperative
agreements between the Foundation and
other entities, including the Food and
Drug Administration, shall promote the
goals and priorities of the Foundation,
shall comply with the Foundation’s
Conflict of Interest policies and shall be
reviewed and approved by the Board of
Directors to ensure that such
requirements are met.
Section 2. Execution. All memoranda
of understanding and cooperative
agreements between the Foundation and
other entities, including the Food and
Drug Administration, shall be signed by
the Executive Director, after obtaining
appropriate approval of the Board of
Directors.
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
E:\FR\FM\22DEN1.SGM
22DEN1
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
other date as may be fixed by resolution
of the Board of Directors.
Section 3. Checks, Notes, Drafts, Etc.
All checks, notes, drafts, or other orders
for the payment of money of the
Foundation shall be signed endorsed, or
accepted in the name of the Foundation
by such officer, person or persons as
from time to time may be designated by
the Board of Directors or by an officer
or officers authorized by the Board of
Directors to make such designation.
Section 4. Execution of Contracts,
Deeds, Etc. The Board of Directors may
authorize any officer or officers, the
Executive Director, or any agent or
agents, in the name and on behalf of the
Foundation to enter into or execute and
deliver any and all deeds, bonds,
mortgages, contracts and other
obligations or instruments, and such
authority may be general or confined to
specific instances.
Section 5. Deposits. All funds of the
Foundation shall be deposited from
time to time to the credit of the
Foundation in such banks, trust
companies or other depositories as the
Board of Directors may select.
Article XV
Amendments
These Bylaws may be amended,
altered or repealed or new Bylaws may
be adopted by a majority of the voting
directors present at any regular meeting
or at any special meeting, if at least two
days written notice is given of intention
to alter, amend, repeal or adopt new
bylaws at such meeting.
srobinson on DSKHWCL6B1PROD with NOTICES
Appendix A to Bylaws
Ethical Guidelines for Identifying and
Managing Conflicts of Interest
Congress created the Reagan-Udall
Foundation (Foundation) to support the
mission of the FDA by identifying,
funding, and supporting projects and
programs that will help equip FDA staff
with the highest caliber science and
technology to enhance the safety and
effectiveness of FDA regulated products.
The Foundation will not participate in
regulatory matters nor will it offer
advice to FDA on policy matters. In
addition, to support its independence
and to maximize its scientific impact,
the Foundation is implementing specific
guidelines and procedures that identify
and avoid potential bias—and
appearances of such bias—and that
provide a transparent process for
individual and institutional decisions.
I. Individual Conflicts
Article VII of the Bylaws describes an
individual’s obligations with respect to
conflicts of interest as follows: ‘‘No
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
director, officer, employee, fellow or
trainee of the Foundation (hereinafter
‘Interested Persons’) shall take any
action on or participate in the
consideration or determination of any
Foundation matter in which he or she,
his or her spouse, minor child, general
partner, non-federal organization in
which he or she is serving as an officer,
director, trustee, general partner or
employee, or any person or nonfederal
organization with whom he or she is
negotiating or has any arrangement
concerning potential employment, has a
financial interest. In addition to actual
conflicts of interest, Interested Persons
are also obliged to avoid actions that
could be perceived or interpreted to be
in conflict with the Foundation’s best
interests. Interested Persons shall
disclose their financial interest in
entities doing business with the
Foundation and refrain from
participating in decisions affecting
transactions between the Foundation
and those other entities without
approval by the Board of Directors.’’
Staff
Goal: To ensure that issues involving
conflicts of interest are addressed when
staff are hired and on an ongoing,
annual basis.
(1) Data Gathering.
The following FDA Financial
Disclosure form is to be filled out by
prospective employees prior to being
hired and filled out annually by
Foundation Employees: FDA’s form for
Senior FDA Employees at https://
www.oge.gov/forms/form_450.aspx.
(2) Process for Review.
The completed form is to be reviewed
by the Foundation’s General Counsel
(hereinafter General Counsel), who will
be responsible for identifying conflicts
and determining what actions would be
necessary to ensure that a prospective or
current employee does not participate in
matters in which such a conflict would
or could exist. The General Counsel will
advise the Executive Committee
regarding such conflicts and necessary
actions.
(3) Process for Addressing Conflicts of
Interest.
The General Counsel will advise the
Executive Committee and the Board
regarding a prospective or current
employee for whom conflicts have been
identified. With respect to a prospective
employee, the Executive Committee will
recommend whether a particular person
should be hired in light of conflicts, and
if so, how such conflicts should be
addressed. If conflicts arise after a
person has been hired, then the
Executive Committee will advise the
Board regarding appropriate steps to be
PO 00000
Frm 00006
Fmt 4703
Sfmt 4703
68033
taken, including divesting holdings
causing the conflict, recusing the
employee from particular matters and
terminating the employee. The Board
will receive all pertinent documents
relating to any conflicts and will make
the final decision with respect to hiring
a person for whom a conflict has been
identified and with respect to
addressing conflicts that have arisen
after an employee has been hired.
Board
Goal: To ensure that the potential for,
or the appearance of, conflicts are
identified, so appropriate steps can be
taken to ensure that the principles in the
Bylaws are met.
(1) Data Gathering.
Upon appointment, and annually
thereafter, each Board member must
provide the General Counsel a signed
statement that lists any interest,
financial or otherwise, that the member,
his or her spouse, minor child, general
partner or employee has in any
company that is regulated by FDA. The
statement will also disclose the identity
of any FDA regulated firm for whom any
adult children of the Board member
works and the nature of any business
that such children have before the
Foundation. Such statement must
describe the nature of the interest but
need not list its monetary value.
(2) Process for Review.
The statement described above will be
reviewed by the Foundation’s General
Counsel, who will be responsible for
identifying conflicts and Foundation
matters from which such Board member
must recuse him or herself from on the
basis of such conflicts. The General
Counsel will advise the Board member
regarding such conflicts and necessary
recusals.
(3) Process for Addressing Conflicts of
Interest.
If it has been determined by the
General Counsel that recusal is
necessary, then the recused Board
member shall not participate in any
discussions or votes regarding the
matter or matters on which he or she
has been recused. Among other things,
a recused Board member shall not
participate in discussions or votes
regarding whether a particular project
should be undertaken by the
Foundation or to whom a project grant
or contract funded by the Foundation
may be awarded.
II. Review of Reagan-Udall Foundation
Projects
Goal: Strictly guard against conflicts
of interest and undue influence while
raising funds for worthwhile
Foundation projects.
E:\FR\FM\22DEN1.SGM
22DEN1
srobinson on DSKHWCL6B1PROD with NOTICES
68034
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 / Notices
Guidelines: Prior to initiation all
specific projects must be reviewed and
approved:
(1) By the Reagan-Udall Board of
Directors.
Before granting its final approval to a
project, the Board shall submit the
project to independent review. In
selecting reviewers, the Board shall
insure that:
• Reviewers are qualified experts on
the relevant topics.
• Each reviewer has certified that he
or she meets the conflict of interest
standard in Article VII.
In the unusual case where a waiver of
this requirement is necessary because
there is no other practical means of
ensuring the necessary expertise, the
name of the reviewer and the
justification for the waiver will be made
public and the Board must determine
that the financial interest is not so
substantial as to be likely to affect the
integrity of the review.
Before granting its final approval to a
project, the Board shall also determine
that:
• Independent review was sufficient
to ensure the objectivity, scientific
validity, and feasibility of the proposal.
• The project is likely to advance the
mission of the FDA to modernize
medical, veterinary, food, food
ingredient, or cosmetic product
development, accelerate innovation, or
enhance product safety.
(2) By a meaningful independent
review.
• For projects with a total budget over
$250,000 (‘‘large projects’’), the Board
may (i) use an existing independent
review process (for example, if one of
the project collaborators is an academic
institution or foundation with an
appropriate independent review
mechanism); or (ii) utilize an ad hoc,
independent panel to review the project.
• For small projects with a total
budget of $250,000 or less (‘‘small
projects’’), the Board may use an
abbreviated independent review
process.
• A majority of reviewers must
determine that the project design is
objective, scientifically valid, and
feasible, and that the project is likely to
advance the mission of the FDA to
modernize medical, veterinary, food,
food ingredient, or cosmetic product
development, accelerate innovation, or
enhance product safety.
III. Policies for Accepting Funds
The Foundation has in place two sets
of guidelines for the acceptance of
funds.
(1) Core Operating Funds can be
accepted from
VerDate Nov<24>2008
18:01 Dec 21, 2009
Jkt 220001
• Federal Government appropriations
process.
• Individuals as tax deductible
donations.
• Foundations and other Not for
Profit organizations.
(2) Project Funds can be accepted
from
• Federal Government appropriations
process.
• Individuals as tax deductible
donations.
• Foundations and other Not for
Profit organizations.
• Other entities.
IV. Violations of Conflicts in Interest
Policy
If the Board of Directors has reason to
believe that a Foundation employee or
Board member has failed to disclose a
conflict, it shall inform the person of the
basis for such belief and afford the
person an opportunity to explain the
alleged failure to disclose. If, after
hearing the response of such person and
making further investigations as may be
warranted, the Board determines that
the employee or Board member has
knowingly or intentionally failed to
disclose a conflict of interest it shall
take appropriate action, including
termination of the employee or Board
member.
V. Transparency
The Foundation will post the
following on its Web site:
(1) The Foundation Bylaws and
Appendix A. Public comment will be
sought on these bylaws and on any
proposed changes prior to adoption.
(2) A statement about RUF’s
commitment to transparency.
(3) A copy of the conflict of interest
form used by Foundation Staff.
(4) Information regarding particular
recusals of Board members or Staff,
including the particular matters on
which the Board member or staff will be
recused and the basis for the recusal.
(5) For each Board member, a list of
any interest, financial or otherwise, that
the member, his or her spouse, minor
child, general partner or employee has
in an FDA-regulated company that
conducts business in areas where the
Foundation is active such that the
interest could pose a potential conflict.
Such statement will describe the nature
of the interest but need not list its
monetary value.
(6) In the unusual case when there is
a waiver of the requirement that a
reviewer have no direct financial
interest in the outcome of a project
because there is no other practical
means of ensuring the necessary
expertise, the name of the reviewer and
the justification for the waiver.
PO 00000
Frm 00007
Fmt 4703
Sfmt 4703
(7) The amount of each donation and
the identity of the donor, including in
kind donations.
(8) Information about each project,
including:
• An Executive Summary, including a
summary of the review process.
• A list of organizational project
participants and their role.
• The identity of all funders.
• A list of Board and/or staff members
who were recused from discussion and
decision making for the project.
(9) The Foundation’s 990 IRS filings
and annual reports (for all years).
(10) A section for questions, feedback
and public input.
Dated: December 15, 2009.
Mark B. McClellan,
Chairman, Reagan-Udall Foundation Board.
[FR Doc. E9–30409 Filed 12–21–09; 8:45 am]
BILLING CODE 4164–04–P
DEPARTMENT OF COMMERCE
Submission for OMB Review;
Comment Request
The Department of Commerce will
submit to the Office of Management and
Budget (OMB) for clearance the
following proposal for collection of
information under the provisions of the
Paperwork Reduction Act (44 U.S.C.
Chapter 35).
Agency: Southeast Region Dealer and
Interview Family of Forms.
OMB Control Number: 0648–0013.
Form Number(s): 88–12, 88–12B, 88–
129, 88–30.
Type of Request: Regular submission.
Number of Respondents: 13,766.
Average Hours per Response: Shrimp
and finfish interviews and dealer quota
reports, 10 minutes; dealer no-purchase
reports, 3 minutes; rock shrimp, golden
crab and coral dealer reports, 15
minutes.
Burden Hours: 1,656.
Needs and Uses: The National Marine
Fisheries Service, Southeast Fisheries
Science Center uses these reporting
instruments to collect landings statistics
and quota monitoring data from
commercial seafood dealers and to
conduct interviews with fishermen for
effort and fishing locations data. This
family of forms includes data collection
activities for monitoring fishery quotas,
routine collections of monthly statistics
from seafood dealers, and interviews
with fishermen to collect catch/effort
and biological data. Collection of
information is authorized by the
development of regional fishery
management councils under the
authority of the Magnuson-Stevens
E:\FR\FM\22DEN1.SGM
22DEN1
Agencies
[Federal Register Volume 74, Number 244 (Tuesday, December 22, 2009)]
[Notices]
[Pages 68028-68034]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-30409]
========================================================================
Notices
Federal Register
________________________________________________________________________
This section of the FEDERAL REGISTER contains documents other than rules
or proposed rules that are applicable to the public. Notices of hearings
and investigations, committee meetings, agency decisions and rulings,
delegations of authority, filing of petitions and applications and agency
statements of organization and functions are examples of documents
appearing in this section.
========================================================================
Federal Register / Vol. 74, No. 244 / Tuesday, December 22, 2009 /
Notices
[[Page 68028]]
REAGAN-UDALL FOUNDATION
The Reagan-Udall Foundation Bylaws
ACTION: Notice; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Reagan-Udall Foundation, which was created by Title VI of
the Food and Drug Administration Amendments of 2007, is publishing the
bylaws that were adopted by its Board of Directors, for public comment.
DATES: Submit e-mail comments to: Comments@ReaganUdall.org on or before
January 21, 2010.
FOR FURTHER INFORMATION CONTACT: Jane Reese-Coulbourne, The Reagan-
Udall Foundation, (202) 783-7877, JRCoulbourne@ReaganUdall.org.
SUPPLEMENTARY INFORMATION:
I. Background
On September 27, 2007, the President signed into law the Food and
Drug Administration Amendments Act of 2007 (FDAAA). Title VI of the law
creates the Reagan-Udall Foundation, the purpose of which is to
``advance the mission of the Food and Drug Administration to modernize
medical, veterinary, food, food ingredient and cosmetic products
development, accelerate innovation, and enhance product safety.'' See
section 770(b) of the act (21 U.S.C. 379dd (b)). The duties of the
Foundation include the identification of unmet needs in the
development, manufacture, and evaluation (including postmarket
evaluation) of the safety and effectiveness of Food and Drug
Administration (FDA)-regulated products, and the establishment of
scientific and other projects and programs to meet those needs. See
section 770(c) (21 U.S.C. 379dd(c)).
Among the areas where experts inside and outside the FDA believe
the Foundation can support better science are:
Scientific fellowships and programs to improve the
scientific capacity of the FDA;
Public-private collaboration to enhance the capacity and
techniques for monitoring the safety of medical products on the market;
Development of methods and analyses to promote the safety
and effectiveness of medical products and foods; and
Improvements in the science and technical capabilities of
food safety.
The Foundation's Board of Directors has adopted an initial set of
bylaws, an important step toward its initiation of activity as a
nonprofit organization. Pursuant to section 770(d)(2) of the act (21
U.S.C. 379dd(d)(2)), these bylaws are being published in the Federal
Register for public comment. The bylaws include provisions on conflicts
of interest and the acceptance of donations and grants. The Foundation
is committed to the highest standards of science in support of FDA's
mission. As the Foundation develops additional information regarding
the types of donations and grants (referred to in the bylaws as
``gifts'') it may receive and the types of projects it will undertake
and fund, it will adopt additional policies regarding conflicts of
interest and other issues. In addition, as the Foundation gains more
experience, it will develop detailed policies and procedures regarding
gift review and acceptance policies. The Foundation will make these
policies and procedures available to the public. Until that time, the
Foundation will not accept donations or grants from entities subject to
FDA regulation or trade associations of industries subject to FDA
regulation. The Board will also monitor the terms of any individual
donation or grant.
II. Bylaws of Reagan-Udall Foundation, Inc., for the Food and Drug
Administration (Adopted by the Board of Directors on October 3, 2009)
Article I
Offices
Section 1. Principal Office. The principal office of the Foundation
shall be at such location as the Board of Directors designates,
however, such location shall, if practicable be located not more than
20 miles from the District of Columbia.
Section 2. Other Offices. The Foundation may also have an office or
offices other than said principal office at such place or places as the
Board of Directors shall from time to time determine or the business of
the Foundation may require. Such other offices shall also, if
practicable, be located not more than 20 miles from the District of
Columbia.
Article II
Mission
Section 1. Mission. The Foundation is organized as a non-profit
organization exclusively for charitable, scientific and educational
purpose as specified in section 501(c)(3) of the Internal Revenue Code
of 1986 and Section 770 of the Federal Food Drug and Cosmetic Act (21
U.S.C. 379dd). The purpose of the Foundation shall be to advance the
mission of the Food and Drug Administration to modernize medical,
veterinary, food, food ingredient, and cosmetic product development,
accelerate innovation, and enhance product safety.
Article III
Members
The Foundation shall have no members. All authority that would
otherwise be vested in or exercised by members shall be vested in the
Board of Directors of the Foundation. Nothing in these bylaws shall be
interpreted as requiring the Board of Directors to meet, vote, or
otherwise act separately as members of the Foundation in order to
exercise powers that would, if there were members of the Foundation, be
vested in the members.
Article IV
Board of Directors
Section 1. General Powers. The business and affairs of the
Foundation shall be managed under the direction of the Board of
Directors. The Board of Directors may exercise all such authority and
powers of the Foundation and do all such lawful acts and things as
provided by statute or the Articles of Incorporation.
Section 2. Composition, Number and Appointment. The Board of
Directors of the Foundation shall be composed of 16 members, two ex
officio members (non-voting) and 14 appointed (voting) members. The ex
officio members shall
[[Page 68029]]
be the following individuals or their designees: The Commissioner of
Food and Drugs and the Director of the National Institutes of Health.
Of the fourteen appointed (voting) members, no more than four members
shall be representatives of the general pharmaceutical, device, food,
cosmetic and biotechnology industries; three shall be representatives
of academic research organizations; two shall be representatives of
patient or consumer advocacy organizations, one shall be a
representative of health care providers; and four or more shall be at
large members with expertise or experience relevant to the purpose of
the Foundation. No employee of the Federal Government shall be
appointed as a member of the Board.
Section 3. Terms of Office. The term of office of each appointed
member of the Board shall be four years except that the terms of
offices for the initial appointed members of the Board shall expire on
a staggered basis as follows: one industry representative, one academic
research representative, and one at-large representative each shall
have an initial appointment of two years; two industry representatives,
one at-large representative, one academic research representative, and
one patient/consumer representative each shall have an initial term of
three years; and one industry representative, two at-large
representatives, one academic research representative, one patient/
consumer representative, and the one health care provider
representative each shall have an initial term of four years. A member
of the Board of Directors may continue to serve after the expiration of
his or her term until a successor is appointed. A member of the Board
of Directors may be reappointed for a subsequent term or terms. If a
member of the Board does not serve the full term, described herein, the
individual appointed, pursuant to section 10, to fill the resulting
vacancy shall be appointed for the remainder of the term of the
predecessor of the individual.
Section 4. Annual Meeting and Annual Reporting. (a) The annual
meeting of the Board of Directors shall be held at such time, but in no
event later than the end of the fifth month following the end of the
fiscal year of the Foundation, and at such place as shall be specified
in a notice thereof given as hereinafter provided in section 7 of this
Article IV or waiver of notice. (b) The annual meeting shall be open to
the public. (c) At the annual meeting the Foundation shall publish a
report for the preceding fiscal year, which shall include a
comprehensive statement of the operations, activities, financial
condition and accomplishments of the Foundation. (d) The Foundation
shall make copies of each report submitted under this section 4 of
Article IV available to any person for a charge not exceeding the cost
of providing such copy.
Section 5. Regular Meeting. Regular meetings of the Board of
Directors shall be held at such time and place as the Board of
Directors may fix.
Section 6. Special Meetings. Special meetings of the Board of
Directors may be called at any time or at the request of the Chair of
the Board or the Executive Director. The person or persons authorized
to call special meetings of the Board may fix the time and place for
holding such special meeting.
Section 7. Notice. Annual and special meetings of the Board of
Directors shall be held on notice to the directors. Notice shall state
the time and place of the meeting and, in the case of a special
meeting, the purpose or purposes for holding such meeting. Notice of
each such meeting shall be sent by electronic mail or mailed, postage
prepaid, to each director, addressed to him or her at his or her
address as shown by the records of the Foundation, at least ten days
before the day on which such meeting is to be held, or under
extraordinary circumstances be delivered to him or her personally or be
given to him or her by telephone, or other similar means, at least
twenty-four hours before the time at which such meeting is to be held.
Notice of any such meeting need not be given to any director who
submits a signed waiver of notice before the meeting or who attends
such meeting without protesting, prior to or at its commencement, the
lack of notice to him or her.
Section 8. Quorum. A majority of the voting members of the entire
Board of Directors shall constitute a quorum for purposes of conducting
the business at any meeting of the Board of Directors; but if less than
a majority of the voting directors are present at said meeting, a
majority of the voting directors present may adjourn the meeting from
time to time without further notice. The Chair may, under extraordinary
circumstances, in his of her discretion, require the vote of the full
Board (all voting members) on a particular matter, provided the Chair
discloses to the Board the basis for requiring such a vote. When the
vote of the full Board is required, voting members will be permitted to
vote at a meeting of the Board or by submitting his or her vote to the
Chair in writing.
Section 9. Manner of Acting. The act of a majority of the voting
directors present at a meeting at which a quorum is present shall be
the act of the Board of Directors, unless the act of a greater number
is required by law or these Bylaws.
Section 10. Vacancies. Any vacancy in the membership of the Board
shall not affect the power of the remaining directors to execute the
duties of the Board and any such vacancy shall be filled promptly by
appointment by the appointed directors by majority vote.
Section 11. Resignations. Any appointed member of the Board of
Directors may resign at any time by giving written notice of his or her
resignation to the Board of Directors, the Chair of the Board, the
Executive Director or the Secretary. Any such resignation shall take
effect at the time specified therein if later than the date of its
receipt, or if the time when it shall become effective is not specified
therein, immediately upon its receipt. Unless otherwise specified
therein, the acceptance of such resignation shall not be necessary to
make it effective.
Section 12. Removal of Directors. Except as otherwise provided by
statute, any director may be removed for cause by the vote of a
majority of the voting members of the Board of Directors then in
office. The failure to participate in at least half of the meetings and
calls scheduled over a one year period shall be a basis for such
removal.
Section 13. Compensation. Members of the Board may not receive
compensation for service on the Board. Directors may be reimbursed for
travel, the reasonable cost of meals and lodging, and other necessary
expenses incurred in carrying out the duties of the Board, as set forth
in these Bylaws.
Section 14. Informal Action by Board of Directors. Any action
required or permitted by law to be taken at a meeting of the Board of
Directors may be taken without a meeting if a unanimous written
consent, which sets forth the action to be taken, shall be signed by
each voting member of the Board and filed with the minutes of
proceedings of the Board.
Section 15. Telephonic Meeting. Members of the Board may
participate in a meeting by means of a telephone conference or similar
communications equipment if all persons participating in the meeting
can hear each other at the same time.
Section 16. Emeritus Directors. The Board of Directors may from
time to time appoint a former director to the honorary position of
``Director Emeritus.'' Unless otherwise determined by the Board of
Directors, the appointment of a Director Emeritus shall continue in
effect for the
[[Page 68030]]
remainder of the person's life. A former director holding such honorary
position shall be entitled to receive notice of, and to attend meetings
or portions of meetings of the Board of Directors, but shall have no
voting or other rights of a director.
Article V
Committees
Section 1. Committees. The Board of Directors, by resolution
adopted by a majority of the voting directors in office, shall
designate and appoint an Executive Committee, a Governance Committee
and a Finance Committee, and may designate and appoint one or more
other committees each of which shall consist of two or more directors,
and delegate to such committees any of the powers of the Board of
Directors, except the power to amend, alter, and repeal the Bylaws; to
elect, appoint or remove any member of such committee or any member of
the Board or any officer of the Foundation; to amend or restate the
Articles of Incorporation; or to adopt a plan of merger or
consolidation with another corporation. The appointment of any
committee, the delegation of authority to it, or action by it under
that authority shall not operate to relieve the Board of Directors, or
any individual member of the Board, of any responsibility imposed upon
it or upon him or her by law.
Section 2. Executive Committee. The Executive Committee shall carry
out the responsibilities of the Board of Directors between meetings of
the Board of Directors.
The Chair of the Board shall be chair of the Executive Committee
and the Secretary of the Foundation shall act as secretary thereof. The
Chairs of the Governance and Finance Committees shall be members of the
Executive Committee. The Executive Director shall be an ex officio,
non-voting member of the Executive Committee. In the absence of the
Chair, Executive Director or Secretary at any meeting of the Executive
Committee, the committee shall appoint a chair or secretary of the
meeting as the case may be.
Section 3. Governance Committee. The Governance Committee shall be
responsible for making recommendations to the Board on all matters
affecting governance, reviewing the Board's performance policies and
these Bylaws, and making recommendations to the Board for director
nominees and Officer appointments. The Vice Chair of the Board shall
chair the Governance Committee.
Section 4. Finance Committee. The Finance Committee shall be
responsible for developing and reviewing fiscal procedures and shall
make recommendations to the Board regarding the budget and other
financial matters. The Treasurer of the Foundation shall chair the
Finance Committee.
Section 5. Term of Office. All committees of the Board of Directors
shall serve at the pleasure of the Board of Directors. Members of
committees who are designated by the Board of Directors shall serve at
the pleasure of the Board of Directors. Each chair of a committee shall
hold such office for one year and until his or her death, resignation
or removal, whichever occurs first. A chair of a committee may continue
to serve as chair after the expiration of his or her term until a
successor is appointed.
Section 6. Organization, Meetings of Committees. The Board of
Directors shall appoint one member of each of the other committees that
may be created to be the chair of such committee. All committees may
adopt rules governing the time, or the method of call or holding their
meetings, and the conduct of their affairs. All committees shall keep a
record of their acts and proceedings and shall report thereon to the
Board of Directors.
Section 7. Vacancies. A vacancy in the membership of any committee
may be filled by appointments made in the same manner as provided in
the case of the original appointments.
Section 8. Quorum. Unless otherwise provided in the resolution of
the Board of Directors designating a committee, a majority of the whole
committee shall constitute a quorum and the act of a majority of the
members present at a meeting at which a quorum is present shall be the
act of the committee.
Article VI
Officers, Employees, Agents and Contractors
Section 1. Number and Qualifications of Officers. The Officers of
the Foundation (except for the initial Chair, which shall be appointed
by the ex-officio directors) shall be elected by the Board of Directors
and shall include the Chair and Vice Chair of the Board, the Secretary,
the Treasurer, and any other officers as may be necessary or desirable
for the business of the Foundation.
Section 2. Election and Term of Office. The officers of the
Foundation, except the Chair of the Board, shall be elected annually by
the members of the Board of Directors at its annual meeting. Each such
officer shall hold office until death, resignation, removal or until
the next annual meeting of the Board of Directors and until his or her
successor shall be duly elected. The members of the Board of Directors
shall elect a member of the Board to serve as the Chair of the Board,
who shall serve through the end of his or her term. An officer may be
re-elected for subsequent terms.
Section 3. Resignations. Any officer of the Foundation may resign
at any time by giving written notice of his or her resignation to the
Board of Directors, the Chair of the Board, the Executive Director or
the Secretary. Any such resignation shall take effect at the time
specified therein or, if the time when it shall become effective is not
specified therein, immediately upon its receipt. Unless otherwise
specified therein, the acceptance of any such resignation shall not be
necessary to make it effective.
Section 4. Removal. Any officer of the Foundation elected or
appointed by the Board of Directors may be removed by an affirmative
vote of a majority of the then incumbent voting members of the Board of
Directors whenever in its judgment the best interests of the Foundation
would be served thereby, but such removal shall be without prejudice to
the contract rights, if any, of the officer so removed.
Section 5. Vacancies. A vacancy in any office because of death,
resignation, removal, disqualification or otherwise shall be filled by
the vote of a majority of the voting members of the Board of Directors
for the unexpired portion of the term.
Section 6. Chair of the Board. The Chair of the Board shall be a
member of the Board, an officer of the Foundation and, if present,
shall preside at each meeting of the Board of Directors. He or she
shall advise and counsel with the Executive Director and in his or her
absence with the other officers of the Foundation, and shall perform
such other duties as may from time to time be assigned to him or her by
the Board of Directors.
Section 7. Vice-Chair of the Board. The Vice-Chair of the Board
shall be a member of the Board, an officer of the Foundation and, if
present, shall preside at each meeting of the Board of Directors at
which the Chair of the Board is not present, and shall perform the
other duties of the Chair of the Board during such times as the Chair
of the Board is unavailable to perform such duties.
Section 8. Treasurer. The Treasurer shall be a member of the Board
and shall (a) Have charge and custody of, and be responsible for, all
the funds and securities of the Foundation; (b) keep or cause to be
kept full and accurate
[[Page 68031]]
accounts of receipts and disbursements in books belonging to the
Foundation; (c) deposit or cause to be deposited all moneys and other
valuables to the credit of the Foundation in such depositories as may
be designated by the Board of Directors or pursuant to its direction;
(d) receive, and give receipts for, moneys due and payable to the
Foundation from any source whatsoever; (e) disburse the funds of the
Foundation; (f) render to the Board of Directors, whenever the Board of
Directors may require, an account of the financial condition of the
Foundation; and (g) in general, perform all duties incident to the
office of Treasurer and such other duties as from time to time may be
assigned to him or her by the Board of Directors.
Section 9. Secretary. The Secretary shall be a member of the Board
and shall (a) Keep or cause to be kept the minutes of all meetings of
the Board of Directors; (b) see that all notices are duly given in
accordance with the provisions of these Bylaws and as required by law;
(c) be custodian of the records and the seal of the Foundation and
affix and attest the seal to all other documents to be executed on
behalf of the Foundation under its seal; (d) see that the books,
reports, statements, certificates, and other documents and records
required by law to be kept and filed are properly kept and filed; (e)
in general, perform all duties incident to the office of Secretary and
such other duties as from time to time may be assigned to him or her by
the Board of Directors.
Section 10. Executive Director. The Board of Directors shall
appoint an Executive Director who shall serve at the pleasure of the
Board of Directors. The Executive Director shall be the chief executive
officer of the Foundation who shall be responsible for the day-to-day
operations of the Foundation. If the Board of Directors has not elected
a Chair or Vice Chair of the Board or if the Chair and Vice Chair of
the Board are absent, the Executive Director shall preside at such
meeting of the Board of Directors. He or she shall perform all duties
incident to the office of the Executive Director and such other duties
as may from time to time be assigned to him or her by the Board of
Directors.
Section 11. Compensation. The Foundation may pay reasonable
compensation for services rendered by employees of the Foundation. All
amounts paid as compensation by the Foundation to any employee shall be
approved by the Board of Directors. The compensation of the Executive
Officer shall not be greater than the compensation of the Commissioner
of the Food and Drug Administration.
Section 12. Agents and Contractors. The Executive Director shall be
responsible for hiring, promoting, and discharging all other employees
and agents of the Foundation. The Executive Director shall also be
responsible for defining the duties of such employees and agents and
determining the compensation to be paid to such employees.
Article VII
Conflicts of Interest
Section 1. General Policy. No director, officer, employee, fellow
or trainee of the Foundation (hereinafter ``Interested Persons'') shall
take any action on or participate in the consideration or determination
of any Foundation matter in which he or she, his or her spouse, minor
child, general partner, non-federal organization in which he or she is
serving as an officer, director, trustee, general partner or employee,
or any person or nonfederal organization with whom he or she is
negotiating or has any arrangement concerning potential employment, has
a financial interest.
Section 2. Responsibilities of Interested Persons. In addition to
actual conflicts of interest, Interested Persons are also obliged to
avoid actions that could be perceived or interpreted to be in conflict
with the Foundation's best interests. Interested Persons shall disclose
their financial interest in entities doing business with the Foundation
and refrain from participating in decisions affecting transactions
between the Foundation and those other entities without approval by the
Board of Directors.
Section 3. Additional Conflict of Interest Policies and Procedures.
Appendix A to these Bylaws includes more detailed policies and
procedures for identifying and managing conflicts of interest.
Section 4. Oversight Responsibilities. The Chair of the Board shall
be responsible for the application of the Foundation's conflicts of
interest policies and procedures to Board Members, committee members,
and the Executive Director. The Executive Director shall be responsible
for the application and interpretation of this policy as it relates to
all other employees, fellows, and trainees.
Section 5. Project Specific Conflicts Policies. The Foundation
shall, as appropriate, develop conflicts of interest policies and
procedures specific to an individual project and/or consortium
developed to carry out the goals of the Foundation. Such policies and
procedures shall be made available to the public.
Article VIII
Acceptance of Donations and Grants
Section 1. General Policy. It shall be the policy of the Foundation
to accept donations and grants (hereinafter ``Gifts'') that further its
missions, supporting the Food and Drug Administration. This mission is
realized through Gifts that support the programs and projects of the
Foundation, Gifts that secure the operation and future growth of the
Foundation, or Gifts that otherwise facilitate the Foundation in
providing services to the Food and Drug Administration. The Board of
Directors shall develop and adopt detailed Gift review and acceptance
policies and procedures that define what constitutes acceptable Gifts.
Such policies and procedures shall be made available to the public. The
Board of Directors shall be responsible for ensuring that the
requirements of this Article VIII and the Foundation's Gift policies
and procedures are met.
Section 2. Review of Gifts. The Board of Directors has the
discretion to accept or refuse all Gifts and is charged with the
responsibility of reviewing and properly screening all Gifts made to
the Foundation. The Board of Directors shall determine whether
acceptance of a gift will reflect unfavorably on, or compromise the
integrity of the Foundation. The Board of Directors shall have the
discretion to refuse any Gift that is deemed inappropriate for any
reason, such as the appearance of, or an actual conflict of interest,
unreasonable or burdensome restrictions, costs to the Foundation in
fulfilling the terms of, or administering the Gift, or any other
reason. The Board of Directors shall make decisions regarding
acceptance or refusal of gifts by a majority of voting members present
at a regularly scheduled meeting of the Board or by a majority of all
voting members if the decision is made between regularly scheduled
meetings. If a vote is taken between regularly scheduled meetings,
members may vote in writing by regular mail or e-mail.
Section 3. Restrictions on Gifts. The Foundation will accept
unrestricted Gifts. The Foundation may also accept Gifts for specific
programs and purposes, provided such Gifts are not inconsistent with
its mission, purposes, and priorities. The Foundation will not accept
Gifts that are too restrictive in purpose or otherwise inappropriate.
Section 4. Availability of Information on Gift Acceptance.
Information about
[[Page 68032]]
the Foundation's acceptance of Gifts shall be made available to the
public.
Article IX
Grants and Contracts
Section 1. Grantee/Contractor Selection and Award Principles. The
selection and award of grants and/or contracts by the Foundation will
be conducted to ensure fairness, impartiality, and inclusiveness. All
grant and contract awards shall be approved by the Board of Directors.
Section 2. Solicitation. The Foundation will take reasonable steps
to make each solicitation widely known to the public.
Section 3. Peer Review. An objective peer-review process will be
used to assess responses to solicitations and provide recommendations
to the Board of Directors.
Section 4. Objectivity. All reviews and assessments shall be made
objectively and shall not be based on commercial or proprietary
interests.
Section 5. Conflicts of Interest. All participants involved in the
development, review, and selection process shall abide by the
Foundation's Conflict of Interest policies.
Section 6. Administrative Expenses Cap. Grants, contracts and
cooperative agreements shall provide that the administrative expenses
allocable to funds provided by the Foundation not exceed 25%.
Section 7. Exclusions. This Article shall not apply to the
selection and award of grants and contracts related to running the day-
to-day operations of the Foundation.
Article X
Information and Inventions
Section 1. Information and Data. All information and data developed
by the Foundation or with Foundation funds shall be released and
published, to the extent practicable, to maximize their use by the Food
and Drug Administration, nonprofit organizations and academic and
industrial researchers to further the goals and priorities of the
Foundation. The Foundation may charge cost-based fees for published
materials produced by the Foundation.
Section 2. Inventions. The Foundation shall ensure that (a) Action
is taken to obtain patents for inventions developed by the Foundation
or with funds from the Foundation; (b) action is taken to enable the
licensing of such inventions; and (c) executed licenses, memoranda of
understanding, material transfer agreements, contracts and other such
instruments promote, to the maximum extent practicable, the broadest
conversion to commercial and noncommercial applications of licensed and
patented inventions of the Foundation to further the goals and
priorities of the Foundation. The Foundation may, consistent with the
policy to support the widest and least restrictive use of inventions,
charge a reasonable royalty for the use of such inventions.
Article XI
Training Fellowships
The Foundation will establish fellowships for: Scientists, doctors
and other professionals, who are not employees of any FDA-regulated
industry; FDA professionals to obtain training outside the agency; and
non-FDA professionals to obtain training at the Foundation, academic or
scientific institutions or the FDA. The purpose of such fellowships
shall be to foster greater understanding of and expertise in new
scientific tools, diagnostics, manufacturing techniques, and potential
barriers to translating basic research into clinical and regulatory
practice, train scientific or regulatory professionals in regulatory
science and policy, and increase the exchange of scientific information
between FDA and external entities.
Article XII
Memoranda of Understanding and Cooperative Agreements
Section 1. Review. All memoranda of understanding and cooperative
agreements between the Foundation and other entities, including the
Food and Drug Administration, shall promote the goals and priorities of
the Foundation, shall comply with the Foundation's Conflict of Interest
policies and shall be reviewed and approved by the Board of Directors
to ensure that such requirements are met.
Section 2. Execution. All memoranda of understanding and
cooperative agreements between the Foundation and other entities,
including the Food and Drug Administration, shall be signed by the
Executive Director, after obtaining appropriate approval of the Board
of Directors.
Article XIII
Indemnification
Section 1. Officers and Directors. To the maximum extent permitted
by the laws of the State of Maryland in effect from time to time, and
subject to compliance with any procedures and other requirements
prescribed by said laws and by such rules and regulations, non
inconsistent with said laws, as the Board of Directors may in its
discretion impose in general or particular cases or classes of cases,
any person who is threatened to be made a party to any threatened,
pending or completed action, suit, or proceeding, whether civil,
criminal, administrative or investigative, by reason of the fact that
he or she is or was a Director or officer of the Foundation shall be
indemnified by the Foundation against judgments, penalties, fines,
settlements, and reasonable expenses, including attorney's fees,
actually and necessarily incurred by him or her in connection with such
action, suit or proceeding, or in connection with any appeal therein
(which reasonable expenses may be paid or reimbursed in advance of
final disposition of any such suit, action, or proceeding subject to
the receipt of a written undertaking to repay such expenses in the
event that such person is determined not to be entitled to be
indemnified).
Section 2. Employees and Agents. To the maximum extent permitted by
the laws of the State of Maryland in effect from time to time, and
subject to compliance with any procedures and other requirements
prescribed by said laws and by such rules and regulations, not
inconsistent with said laws, as the Board of Directors may in its
discretion impose in general or particular cases or classes of cases,
any person who is threatened to be made a party to any threatened,
pending or completed action, suit, or proceeding, whether civil,
criminal, administrative or investigative, by reason of the fact that
he or she is or was an employee or agent of the Foundation may (but
need not) be indemnified by the Foundation against judgments,
penalties, fines, settlements, and reasonable expenses, including
attorney's fees, actually and necessarily incurred by him or her in
connection with such action, suit or proceeding, or in connection with
any appeal therein (which reasonable expenses may be paid or reimbursed
in advance of final disposition of any such suit, action, or proceeding
subject to the receipt of a written undertaking to repay such expenses
in the event that such person is determined not to be entitled to be
indemnified).
Article XIV
General Provisions
Section 1. Seal. The seal of the Foundation shall be in such form
as shall be approved by the Board of Directors.
Section 2. Fiscal Year. The fiscal year of the Foundation shall end
on December 31 of each year or on such
[[Page 68033]]
other date as may be fixed by resolution of the Board of Directors.
Section 3. Checks, Notes, Drafts, Etc. All checks, notes, drafts,
or other orders for the payment of money of the Foundation shall be
signed endorsed, or accepted in the name of the Foundation by such
officer, person or persons as from time to time may be designated by
the Board of Directors or by an officer or officers authorized by the
Board of Directors to make such designation.
Section 4. Execution of Contracts, Deeds, Etc. The Board of
Directors may authorize any officer or officers, the Executive
Director, or any agent or agents, in the name and on behalf of the
Foundation to enter into or execute and deliver any and all deeds,
bonds, mortgages, contracts and other obligations or instruments, and
such authority may be general or confined to specific instances.
Section 5. Deposits. All funds of the Foundation shall be deposited
from time to time to the credit of the Foundation in such banks, trust
companies or other depositories as the Board of Directors may select.
Article XV
Amendments
These Bylaws may be amended, altered or repealed or new Bylaws may
be adopted by a majority of the voting directors present at any regular
meeting or at any special meeting, if at least two days written notice
is given of intention to alter, amend, repeal or adopt new bylaws at
such meeting.
Appendix A to Bylaws
Ethical Guidelines for Identifying and Managing Conflicts of Interest
Congress created the Reagan-Udall Foundation (Foundation) to
support the mission of the FDA by identifying, funding, and supporting
projects and programs that will help equip FDA staff with the highest
caliber science and technology to enhance the safety and effectiveness
of FDA regulated products. The Foundation will not participate in
regulatory matters nor will it offer advice to FDA on policy matters.
In addition, to support its independence and to maximize its scientific
impact, the Foundation is implementing specific guidelines and
procedures that identify and avoid potential bias--and appearances of
such bias--and that provide a transparent process for individual and
institutional decisions.
I. Individual Conflicts
Article VII of the Bylaws describes an individual's obligations
with respect to conflicts of interest as follows: ``No director,
officer, employee, fellow or trainee of the Foundation (hereinafter
`Interested Persons') shall take any action on or participate in the
consideration or determination of any Foundation matter in which he or
she, his or her spouse, minor child, general partner, non-federal
organization in which he or she is serving as an officer, director,
trustee, general partner or employee, or any person or nonfederal
organization with whom he or she is negotiating or has any arrangement
concerning potential employment, has a financial interest. In addition
to actual conflicts of interest, Interested Persons are also obliged to
avoid actions that could be perceived or interpreted to be in conflict
with the Foundation's best interests. Interested Persons shall disclose
their financial interest in entities doing business with the Foundation
and refrain from participating in decisions affecting transactions
between the Foundation and those other entities without approval by the
Board of Directors.''
Staff
Goal: To ensure that issues involving conflicts of interest are
addressed when staff are hired and on an ongoing, annual basis.
(1) Data Gathering.
The following FDA Financial Disclosure form is to be filled out by
prospective employees prior to being hired and filled out annually by
Foundation Employees: FDA's form for Senior FDA Employees at https://www.oge.gov/forms/form_450.aspx.
(2) Process for Review.
The completed form is to be reviewed by the Foundation's General
Counsel (hereinafter General Counsel), who will be responsible for
identifying conflicts and determining what actions would be necessary
to ensure that a prospective or current employee does not participate
in matters in which such a conflict would or could exist. The General
Counsel will advise the Executive Committee regarding such conflicts
and necessary actions.
(3) Process for Addressing Conflicts of Interest.
The General Counsel will advise the Executive Committee and the
Board regarding a prospective or current employee for whom conflicts
have been identified. With respect to a prospective employee, the
Executive Committee will recommend whether a particular person should
be hired in light of conflicts, and if so, how such conflicts should be
addressed. If conflicts arise after a person has been hired, then the
Executive Committee will advise the Board regarding appropriate steps
to be taken, including divesting holdings causing the conflict,
recusing the employee from particular matters and terminating the
employee. The Board will receive all pertinent documents relating to
any conflicts and will make the final decision with respect to hiring a
person for whom a conflict has been identified and with respect to
addressing conflicts that have arisen after an employee has been hired.
Board
Goal: To ensure that the potential for, or the appearance of,
conflicts are identified, so appropriate steps can be taken to ensure
that the principles in the Bylaws are met.
(1) Data Gathering.
Upon appointment, and annually thereafter, each Board member must
provide the General Counsel a signed statement that lists any interest,
financial or otherwise, that the member, his or her spouse, minor
child, general partner or employee has in any company that is regulated
by FDA. The statement will also disclose the identity of any FDA
regulated firm for whom any adult children of the Board member works
and the nature of any business that such children have before the
Foundation. Such statement must describe the nature of the interest but
need not list its monetary value.
(2) Process for Review.
The statement described above will be reviewed by the Foundation's
General Counsel, who will be responsible for identifying conflicts and
Foundation matters from which such Board member must recuse him or
herself from on the basis of such conflicts. The General Counsel will
advise the Board member regarding such conflicts and necessary
recusals.
(3) Process for Addressing Conflicts of Interest.
If it has been determined by the General Counsel that recusal is
necessary, then the recused Board member shall not participate in any
discussions or votes regarding the matter or matters on which he or she
has been recused. Among other things, a recused Board member shall not
participate in discussions or votes regarding whether a particular
project should be undertaken by the Foundation or to whom a project
grant or contract funded by the Foundation may be awarded.
II. Review of Reagan-Udall Foundation Projects
Goal: Strictly guard against conflicts of interest and undue
influence while raising funds for worthwhile Foundation projects.
[[Page 68034]]
Guidelines: Prior to initiation all specific projects must be
reviewed and approved:
(1) By the Reagan-Udall Board of Directors.
Before granting its final approval to a project, the Board shall
submit the project to independent review. In selecting reviewers, the
Board shall insure that:
Reviewers are qualified experts on the relevant topics.
Each reviewer has certified that he or she meets the
conflict of interest standard in Article VII.
In the unusual case where a waiver of this requirement is necessary
because there is no other practical means of ensuring the necessary
expertise, the name of the reviewer and the justification for the
waiver will be made public and the Board must determine that the
financial interest is not so substantial as to be likely to affect the
integrity of the review.
Before granting its final approval to a project, the Board shall
also determine that:
Independent review was sufficient to ensure the
objectivity, scientific validity, and feasibility of the proposal.
The project is likely to advance the mission of the FDA to
modernize medical, veterinary, food, food ingredient, or cosmetic
product development, accelerate innovation, or enhance product safety.
(2) By a meaningful independent review.
For projects with a total budget over $250,000 (``large
projects''), the Board may (i) use an existing independent review
process (for example, if one of the project collaborators is an
academic institution or foundation with an appropriate independent
review mechanism); or (ii) utilize an ad hoc, independent panel to
review the project.
For small projects with a total budget of $250,000 or less
(``small projects''), the Board may use an abbreviated independent
review process.
A majority of reviewers must determine that the project
design is objective, scientifically valid, and feasible, and that the
project is likely to advance the mission of the FDA to modernize
medical, veterinary, food, food ingredient, or cosmetic product
development, accelerate innovation, or enhance product safety.
III. Policies for Accepting Funds
The Foundation has in place two sets of guidelines for the
acceptance of funds.
(1) Core Operating Funds can be accepted from
Federal Government appropriations process.
Individuals as tax deductible donations.
Foundations and other Not for Profit organizations.
(2) Project Funds can be accepted from
Federal Government appropriations process.
Individuals as tax deductible donations.
Foundations and other Not for Profit organizations.
Other entities.
IV. Violations of Conflicts in Interest Policy
If the Board of Directors has reason to believe that a Foundation
employee or Board member has failed to disclose a conflict, it shall
inform the person of the basis for such belief and afford the person an
opportunity to explain the alleged failure to disclose. If, after
hearing the response of such person and making further investigations
as may be warranted, the Board determines that the employee or Board
member has knowingly or intentionally failed to disclose a conflict of
interest it shall take appropriate action, including termination of the
employee or Board member.
V. Transparency
The Foundation will post the following on its Web site:
(1) The Foundation Bylaws and Appendix A. Public comment will be
sought on these bylaws and on any proposed changes prior to adoption.
(2) A statement about RUF's commitment to transparency.
(3) A copy of the conflict of interest form used by Foundation
Staff.
(4) Information regarding particular recusals of Board members or
Staff, including the particular matters on which the Board member or
staff will be recused and the basis for the recusal.
(5) For each Board member, a list of any interest, financial or
otherwise, that the member, his or her spouse, minor child, general
partner or employee has in an FDA-regulated company that conducts
business in areas where the Foundation is active such that the interest
could pose a potential conflict. Such statement will describe the
nature of the interest but need not list its monetary value.
(6) In the unusual case when there is a waiver of the requirement
that a reviewer have no direct financial interest in the outcome of a
project because there is no other practical means of ensuring the
necessary expertise, the name of the reviewer and the justification for
the waiver.
(7) The amount of each donation and the identity of the donor,
including in kind donations.
(8) Information about each project, including:
An Executive Summary, including a summary of the review
process.
A list of organizational project participants and their
role.
The identity of all funders.
A list of Board and/or staff members who were recused from
discussion and decision making for the project.
(9) The Foundation's 990 IRS filings and annual reports (for all
years).
(10) A section for questions, feedback and public input.
Dated: December 15, 2009.
Mark B. McClellan,
Chairman, Reagan-Udall Foundation Board.
[FR Doc. E9-30409 Filed 12-21-09; 8:45 am]
BILLING CODE 4164-04-P